Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 5/20 | 0.74 |
| ▸ | TMPRSS4 | Q9NRS4 | 7/20 | 0.39 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2551428 | 0.94 | NR3C2 (0.74) | NR3C2TMPRSS4NPSR1L3MBTL1MAPT | |
| SCHEMBL27997696 | 0.93 | NR3C2 (0.81) | NR3C2TMPRSS4NPSR1L3MBTL1MAPT | |
| SCHEMBL2359248 | 0.93 | NR3C2 (0.81) | NR3C2TMPRSS4NPSR1L3MBTL1MAPT | |
| SCHEMBL2359459 | 0.91 | NR3C2 (0.61) | NR3C2MAPT | |
| SCHEMBL2358524 | 0.91 | NR3C2 (0.60) | NR3C2PTGES2NPSR1MAPTMAPK1 | |
| SCHEMBL2357191 | 0.88 | NR3C2 (0.58) | NR3C2P2RX1 | |
| SCHEMBL16456948 | 0.87 | NR3C2 (0.57) | NR3C2TMPRSS4PTGES2NPSR1MAPT | |
| SCHEMBL2358468 | 0.87 | NR3C2 (0.64) | NR3C2TMPRSS4 | |
| SCHEMBL2356581 | 0.85 | NR3C2 (1.00) | NR3C2TMPRSS4NPSR1L3MBTL1MAPT | |
| SCHEMBL2357294 | 0.84 | NR3C2 (0.67) | NR3C2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642640-B2 | 1-phenylpyrrole derivatives | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642640-B2 | 1-phenylpyrrole derivatives | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642640-B2 | 1-phenylpyrrole derivatives | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2349996-B1 | 1-PHENYLPYRROLE COMPOUNDS | EXELIXIS INC (US) | 2014-01-01 | — | — | EP | disclosed |
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | REN, AGTR1, NR3C2 | NR3C2 3/4885TMPRSS4 2699/4885PTGES2 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.